Exane Derivatives Kiniksa Pharmaceuticals, Ltd. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Kiniksa Pharmaceuticals, Ltd. stock. As of the latest transaction made, Exane Derivatives holds 9,496 shares of KNSA stock, worth $239,868. This represents 0.06% of its overall portfolio holdings.
Number of Shares
9,496
Previous 9,496
-0.0%
Holding current value
$239,868
Previous $94,000
2.13%
% of portfolio
0.06%
Previous 0.03%
Shares
9 transactions
Others Institutions Holding KNSA
# of Institutions
11Shares Held
1.89MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V81.52MShares$38.3 Million0.03% of portfolio
-
Spearhead Capital Advisors, LLC Wellington, FL203KShares$5.12 Million2.82% of portfolio
-
Putnam Investments LLC Boston, MA39.5KShares$997,4160.0% of portfolio
-
Barclays PLC London, X034.8KShares$880,0330.0% of portfolio
-
Birchview Capital, LP Burlington, VT30KShares$757,8000.56% of portfolio
About Kiniksa Pharmaceuticals, Ltd.
- Ticker KNSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,470,400
- Market Cap $871M
- Description
- Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...